Viral vector vaccines to treat colorectal cancer

N. Ashraf, Amit Mahipal, Richard Kim

Research output: Contribution to journalArticle

Abstract

Despite recent advances in the diagnosis and treatment of colorectal cancer, it remains the second commonest cause of cancer deaths in the USA. Current therapeutic agents have provided a small, incremental survival benefit at the cost of significantly increased toxicities. There is a huge unmet need for novel effective therapies. Colorectal cancer evades the host immune surveillance as a result of weak immunogenicity and immunosuppressive effects of cancer cells. Cancer vaccines have the potential to activate the immune system against colorectal cancer cells by increasing the expression and presentation of tumor-associated antigens. Recent clinical trials using viral-vector-based cancer vaccines have demonstrated clinical benefit with excellent safety profiles in patients with metastatic colorectal cancer. Here, we review the rationale for immunotherapy in colon cancer; clinical trial data for viral-vector-based colorectal cancer vaccines, the advantages and disadvantages of viral vectors, and future treatment strategies.

Original languageEnglish (US)
Pages (from-to)398-405
Number of pages8
JournalCurrent Colorectal Cancer Reports
Volume9
Issue number4
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Fingerprint

Viral Vaccines
Colorectal Neoplasms
Cancer Vaccines
Clinical Trials
Neoplasm Antigens
Therapeutics
Immunosuppressive Agents
Immunotherapy
Colonic Neoplasms
Cause of Death
Immune System
Neoplasms
Safety
Survival

Keywords

  • Colon cancer
  • Colon cancer immunogenicity
  • Immunotherapy
  • Review
  • Vaccine
  • Viral vaccines

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology

Cite this

Viral vector vaccines to treat colorectal cancer. / Ashraf, N.; Mahipal, Amit; Kim, Richard.

In: Current Colorectal Cancer Reports, Vol. 9, No. 4, 01.12.2013, p. 398-405.

Research output: Contribution to journalArticle

Ashraf, N. ; Mahipal, Amit ; Kim, Richard. / Viral vector vaccines to treat colorectal cancer. In: Current Colorectal Cancer Reports. 2013 ; Vol. 9, No. 4. pp. 398-405.
@article{01edc9229ac34c959c05362f486e0cf2,
title = "Viral vector vaccines to treat colorectal cancer",
abstract = "Despite recent advances in the diagnosis and treatment of colorectal cancer, it remains the second commonest cause of cancer deaths in the USA. Current therapeutic agents have provided a small, incremental survival benefit at the cost of significantly increased toxicities. There is a huge unmet need for novel effective therapies. Colorectal cancer evades the host immune surveillance as a result of weak immunogenicity and immunosuppressive effects of cancer cells. Cancer vaccines have the potential to activate the immune system against colorectal cancer cells by increasing the expression and presentation of tumor-associated antigens. Recent clinical trials using viral-vector-based cancer vaccines have demonstrated clinical benefit with excellent safety profiles in patients with metastatic colorectal cancer. Here, we review the rationale for immunotherapy in colon cancer; clinical trial data for viral-vector-based colorectal cancer vaccines, the advantages and disadvantages of viral vectors, and future treatment strategies.",
keywords = "Colon cancer, Colon cancer immunogenicity, Immunotherapy, Review, Vaccine, Viral vaccines",
author = "N. Ashraf and Amit Mahipal and Richard Kim",
year = "2013",
month = "12",
day = "1",
doi = "10.1007/s11888-013-0185-2",
language = "English (US)",
volume = "9",
pages = "398--405",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "4",

}

TY - JOUR

T1 - Viral vector vaccines to treat colorectal cancer

AU - Ashraf, N.

AU - Mahipal, Amit

AU - Kim, Richard

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Despite recent advances in the diagnosis and treatment of colorectal cancer, it remains the second commonest cause of cancer deaths in the USA. Current therapeutic agents have provided a small, incremental survival benefit at the cost of significantly increased toxicities. There is a huge unmet need for novel effective therapies. Colorectal cancer evades the host immune surveillance as a result of weak immunogenicity and immunosuppressive effects of cancer cells. Cancer vaccines have the potential to activate the immune system against colorectal cancer cells by increasing the expression and presentation of tumor-associated antigens. Recent clinical trials using viral-vector-based cancer vaccines have demonstrated clinical benefit with excellent safety profiles in patients with metastatic colorectal cancer. Here, we review the rationale for immunotherapy in colon cancer; clinical trial data for viral-vector-based colorectal cancer vaccines, the advantages and disadvantages of viral vectors, and future treatment strategies.

AB - Despite recent advances in the diagnosis and treatment of colorectal cancer, it remains the second commonest cause of cancer deaths in the USA. Current therapeutic agents have provided a small, incremental survival benefit at the cost of significantly increased toxicities. There is a huge unmet need for novel effective therapies. Colorectal cancer evades the host immune surveillance as a result of weak immunogenicity and immunosuppressive effects of cancer cells. Cancer vaccines have the potential to activate the immune system against colorectal cancer cells by increasing the expression and presentation of tumor-associated antigens. Recent clinical trials using viral-vector-based cancer vaccines have demonstrated clinical benefit with excellent safety profiles in patients with metastatic colorectal cancer. Here, we review the rationale for immunotherapy in colon cancer; clinical trial data for viral-vector-based colorectal cancer vaccines, the advantages and disadvantages of viral vectors, and future treatment strategies.

KW - Colon cancer

KW - Colon cancer immunogenicity

KW - Immunotherapy

KW - Review

KW - Vaccine

KW - Viral vaccines

UR - http://www.scopus.com/inward/record.url?scp=84892440087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892440087&partnerID=8YFLogxK

U2 - 10.1007/s11888-013-0185-2

DO - 10.1007/s11888-013-0185-2

M3 - Article

AN - SCOPUS:84892440087

VL - 9

SP - 398

EP - 405

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 4

ER -